veski news

veski innovation fellow, Professor Mark Dawson has been recognised in the 2020 Prime Minister’s Prizes for Science for his pioneering research in the field of epigenetics and its impact on human health and disease.

Professor Dawson was awarded the prestigious Frank Fenner Prize for Life Scientist of the Year, in an evening ceremony conducted online due to COVID-19.

Professor Mark Dawson was one of three researchers to receive funding from the Federal Government’s Stem Cell Therapies Mission, through The Centre for Stem Cell Systems, to further understanding of leukaemia and explore new stem-cell based therapies to treat this currently incurable condition.

Assoc Prof Seth Masters has published a paper in Nature Communications - ‘A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction’.

Prof Mark Dawson was successful in the latest round of NHMRC funding, receiving an Investigator Grant, Leadership 1, improving outcomes for cancer patients by targeting the epigenome $2,258,892, with Prof Sarah Jane Dawson, veski connected community member, also receiving an Investigator Grant of $1,544,066.

Mark Dawson - Improving outcomes for cancer patients by targeting the epigenome

Associate Professor Emma Sciberras: Improving outcomes for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) and their carers ($1,544,073)

Victoria Prize for Science and Innovation in 2020

Before COVID-19 struck, Natalia Rodriguez had been travelling from Launceston to The Alfred Oncology Unit every three weeks to take part in a clinical trial that could save her life.

The mum of two has cervical cancer, and the phase 1 trial of two immunotherapy drugs, which are still undergoing early testing, had already shown promise in shrinking the tumours that had spread throughout her body.

veski is Calling for Applications for the veski inspiring women STEM sidebyside program for a third consecutive year - exclusively for a cohort of competitively selected mid-career emerging leaders.